Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2042009 | 1.00 | CYP2D6 (0.40) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL2037723 | 0.80 | CYP2D6 (0.41) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL18220751 | 0.78 | ACE (0.54) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL14809033 | 0.76 | CYP2D6 (0.44) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL10734273 | 0.75 | CA1 (0.46) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL6913491 | 0.74 | CA1 (0.50) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL7064883 | 0.74 | CA1 (0.50) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL919145 | 0.74 | CA1 (0.50) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL9518399 | 0.74 | CYP2D6 (0.49) | CYP2D6CA1CA2CA4KMT2A | |
| SCHEMBL7632295 | 0.73 | KMT2A (0.48) | CYP2D6CA1CA2CA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685705-B2 | Method for producing α-allylated cycloalkanone | KAO CORPORATION (JP) | 2023-06-27 | — | — | US | disclosed |
| US-20220153672-A1 | METHOD FOR PRODUCING ALPHA-ALLYLATED CYCLOALKANONE | KAO CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| EP-3943476-A1 | METHOD FOR PRODUCING alpha- ALLYLATED CYCLOALKANONE | Kao Corporation (JP) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020189670-A1 | METHOD FOR PRODUCING α – ALLYLATED CYCLOALKANONE | 花王株式会社 | 2020-09-24 | — | — | WO | disclosed |
| WO-2011073843-A1 | ODORANT ALCOHOLS | FIRMENICH SA (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153672-A1 | METHOD FOR PRODUCING ALPHA-ALLYLATED CYCLOALKANONE | AKR1C3, PYM1, AKR1A1 | CYP2D6 401/4885CA1 2286/4885CA2 2777/4885 |
| US-11685705-B2 | Method for producing α-allylated cycloalkanone | AKR1C3, GALK1, PYM1 | CYP2D6 442/4885CA1 2387/4885CA2 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.